Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Stiolto Respimat combines tiotropium bromide, an anticholinergic, and olodaterol, a long-acting beta2-adrenergic agonist (LABA). Stiolto is administered via the Respimat Inhaler that delivers a slow-moving mist to help patients inhale the medication.

The FDA approval was based on Phase 3 TONADO 1 and 2 randomized, double-blind, active-controlled trials that evaluated over 5,000 patients with COPD. Study data showed it provided statistically significant improvements in lung function at 24 weeks vs. tiotropium and olodaterol alone.

RELATED: Combination COPD Therapy Improves Lung Function in Trials

Stiolto Respimat will be available as a 3.124mcg/2.736mcg (equivalent to 2.5mcg/2.5mcg) strength. It will be supplied as a carton containing one cartridge and one inhaler providing 60 metered actuations.

For more information call (800) 542-6257 or visit